ALK融合基因阳性非小细胞肺癌的研究进展 Translated title: Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer

Abstract

ALK基因重排在非小细胞肺癌（non-small cell lung cancer, NSCLC）中发生率约3%-5%。 ALK基因抑制剂近年来取得极大突破，明显延长了ALK阳新晚期NSCLC患者的生存期；但大部分患者持续用药后会出现获得性耐药。本文分别从 ALK基因背景、检测方法、三代ALK抑制剂的治疗效果以及耐药后的策略、展望进行了阐述。希望对临床工作有参考价值和借鉴意义。

Translated abstract

The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.